🔍

Emmessar Biotech & Nutrition Ltd (524768)

📊 BSE: 524768 🏢 Commodity Chemicals 📢 Latest filing: 02 Oct 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Emmessar Biotech's revenue was ₹0.1 Cr (-34.1% year on year, -34.1% on the previous quarter), and net profit ₹0.1 Cr (-22.6% year on year); the operating margin was -594.9%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹0.1	-34.1%	-34.1%
Operating profit	₹-0.4	loss widened	loss narrowed
Net profit	₹0.1	-22.6%	+338.3%
EPS (₹)	0.26	-23.5%	+333.3%
Operating margin	-594.9%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Emmessar Biotech Publishes Newspaper Notice for Physical Shares Re-lodgement; Reports Nil Requests

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 02 Oct 2026, 02:55 PM

Emmessar Biotech & Nutrition Ltd has published newspaper notices in The Free Press Journal and Navshakti regarding a special window for re-lodgement of transfer requests for physical shares, pursuant to SEBI circulars. The company confirmed that no requests for re-lodgement of physical share transfers were received from shareholders. Necessary reporting has been completed by its RTA, MUFG Intime India Private Limited. This is a standard statutory compliance filing with zero operational or financial impact on the company.

Published newspaper notices in 'The Free Press Journal' and 'Navshakti' on October 02, 2026
Issued in compliance with SEBI circular dated January 30, 2026, and July 02, 2025
Confirmed zero (nil) transfer requests received for physical shares re-lodgement
Compliance reporting submitted to SEBI by RTA MUFG Intime India Private Limited

💡 No action required. Investors should track regular quarterly operational performance and upcoming quarterly financial results.

Emmessar Biotech AGM Approves Re-Appointments with 95.3% Votes in Favor

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Sep 2026, 01:28 PM

Emmessar Biotech & Nutrition Ltd submitted the Scrutinizer's Report for its 34th Annual General Meeting held on September 29, 2026. All 4 resolutions, including the adoption of FY26 financial statements and 5-year re-appointments of MD Srinivasa Raghavan Mathurakavi Ayyangar and Whole-time Director Jeyavel Balaiah Nadar, were approved. Across all resolutions, 95.31% of polled votes were cast in favor (15,95,343 votes) and 4.69% against (78,553 votes). Notably, public non-institutional voters opposed the resolutions with 74.98% of their polled votes cast against, though promoters held sufficient voting power (15,69,127 votes) to pass them.

All 4 resolutions passed with 95.3072% votes in favor and 4.6928% against
Total votes polled stood at 16,73,896, representing 33.5041% of outstanding shares
Managing Director Srinivasa Raghavan Mathurakavi Ayyangar re-appointed for a 5-year term
Whole-time Director Jeyavel Balaiah Nadar re-appointed for a 5-year term
Public non-institutional shareholders cast 78,553 votes (74.9773% of their polled votes) against each resolution

💡 Track the company's upcoming Q2 FY27 earnings to monitor operational performance given negligible FY26 annual revenues of Rs 0.36 Cr.

Emmessar Biotech Issues Newspaper Notice for 34th AGM on September 29, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Aug 2026, 02:40 PM

Emmessar Biotech & Nutrition Ltd has submitted copies of newspaper advertisements regarding its upcoming 34th Annual General Meeting (AGM). The AGM is scheduled to be held via Video Conferencing (VC) on September 29, 2026. The notice was published in The Free Press Journal (English) and Navashakti (Marathi) editions as per regulatory requirements.

34th Annual General Meeting scheduled for September 29, 2026
AGM to be conducted via Video Conferencing (VC)
Notices published in The Free Press Journal and Navashakti on August 27, 2026

💡 Shareholders should look out for the detailed AGM notice and FY26 annual report to evaluate management commentary and voting agenda items.

Emmessar Biotech & Nutrition Ltd Publishes Q1 FY27 Results in Newspapers

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Aug 2026, 02:17 PM

Emmessar Biotech & Nutrition Ltd has submitted copies of its audited financial results for the quarter ended June 30, 2026, as published in the Free Press Journal and Nav Shakti. This is a routine regulatory filing under SEBI (LODR) Regulations, 2015. Given the company's micro-cap status (Rs 13 Cr) and negligible TTM revenue (Rs 0 Cr), this announcement is purely administrative and does not reflect new operational developments.

Financial results published for the quarter ended June 30, 2026
Compliance filing pursuant to Regulation 30 and 47 of SEBI Listing Regulations
Advertisements appeared in Free Press Journal and Nav Shakti on August 8, 2026
Company maintains a small market capitalization of approximately Rs 13 Cr

💡 Investors should monitor the full financial statements on the stock exchange to check for any signs of operational revival, as the company currently reports zero TTM revenue.

Rs 13.15 Lakh Q1 Profit: Emmessar Biotech Reports 23% YoY Decline in Net Profit

🟡 NEUTRAL ⭐ 5/10

EARNINGS 📅 07 Aug 2026, 02:05 PM

Emmessar Biotech & Nutrition Ltd reported a net profit of Rs 13.15 Lakhs for Q1 FY27 (ended June 30, 2026), down 23.2% from Rs 17.12 Lakhs in the year-ago period. Revenue from operations (Healthcare segment) fell 36% YoY to Rs 5.93 Lakhs. The company remains heavily dependent on 'Rent on Leasehold Land,' which contributed Rs 41.33 Lakhs to segment revenue, significantly more than its core operations. Total expenses rose to Rs 43.55 Lakhs, driven by a 23.7% increase in employee benefit costs.

Net Profit after tax stood at Rs 13.15 Lakhs vs Rs 17.12 Lakhs in Q1 FY26.
Revenue from operations declined to Rs 5.93 Lakhs from Rs 9.28 Lakhs YoY.
Rental income from leasehold land remained stagnant at Rs 41.33 Lakhs for the quarter.
Employee benefit expenses increased to Rs 30.32 Lakhs from Rs 24.50 Lakhs YoY.
Basic and Diluted EPS decreased to Rs 0.26 from Rs 0.34 YoY.

💡 Investors should monitor if the company can scale its Healthcare segment, as current profitability is almost entirely supported by rental income. The upcoming AGM on September 29, 2026, may provide more clarity on business strategy.

Q1 Net Profit at ₹13.15 Lakhs; Core Healthcare Revenue Declines 36% YoY

🟡 NEUTRAL ⭐ 5/10

EARNINGS 📅 07 Aug 2026, 02:00 PM

Emmessar Biotech reported a weak operational performance for Q1 FY27, with core healthcare revenue falling to ₹5.93 Lakhs from ₹9.28 Lakhs YoY. Total income of ₹59.85 Lakhs was primarily sustained by rental income from leasehold land (₹41.33 Lakhs) and other income. Net profit for the quarter stood at ₹13.15 Lakhs, a 23% decline from ₹17.12 Lakhs in the same quarter last year. The company remains a micro-cap entity with a ₹12 Cr market cap and minimal operational scale in its primary industry.

Revenue from operations dropped 36% YoY to ₹5.93 Lakhs from ₹9.28 Lakhs.
Rental income from leasehold land contributed ₹41.33 Lakhs, representing 69% of total income.
Net profit for the quarter ended June 2026 was ₹13.15 Lakhs, down from ₹17.12 Lakhs YoY.
Total expenses increased to ₹43.55 Lakhs compared to ₹39.57 Lakhs in the previous year's quarter.
The 34th Annual General Meeting is scheduled for September 29, 2026, via video conferencing.

💡 Monitor management commentary during the upcoming AGM on September 29 regarding the strategy to scale the healthcare segment, as the current business is primarily driven by rental income.

Emmessar Biotech Board Meeting on August 07, 2026, to Approve Q1 FY27 Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 01 Aug 2026, 03:51 PM

Emmessar Biotech & Nutrition Ltd has scheduled a board meeting for August 07, 2026, to consider and approve unaudited financial results for the quarter ended June 30, 2026. The company is a micro-cap entity with a market capitalization of just ₹12 Cr and reported a very low TTM revenue of ₹0.37 Cr. The trading window for insiders will remain closed until August 09, 2026. Given the company's negative operating margins (-375% TTM), the upcoming results will be critical to assess if there is any improvement in core business operations.

Board meeting scheduled for August 07, 2026, to approve Q1 results.
Trading window for equity shares closed until August 09, 2026.
Company reported a small TTM revenue of ₹0.37 Cr against a market cap of ₹12 Cr.
Operating profit margin remains highly negative at -375% as per TTM data.

💡 Monitor the financial results on August 07, 2026, to check for any signs of revenue growth or reduction in operating losses, as the company currently operates at a very small scale.

Emmessar Biotech Reports Zero Requests in Physical Share Transfer Re-lodgement Window

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 01 Aug 2026, 03:50 PM

Emmessar Biotech & Nutrition Ltd has completed a regulatory requirement by providing a special window for the re-lodgement of physical share transfer requests. The company published newspaper advertisements in 'The Free Press Journal' and 'Navshakti' on August 1, 2026, as per SEBI circulars. The company confirmed that no requests for re-lodgement were received from shareholders during this period. This is a procedural update and does not impact the company's financial position or operations.

Published newspaper advertisements in two editions on August 1, 2026, regarding share transfers.
Zero (0) requests were received from shareholders for the re-lodgement of physical share transfers.
Compliance maintained with SEBI Circular No. SEBI/HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026.
Registrar and Transfer Agent (RTA) MUFG Intime India Private Limited handled the reporting to SEBI.

💡 This is a routine administrative filing. Investors holding physical shares should ensure they are aware of SEBI's dematerialization requirements, but no specific action is needed for this announcement.

View All 524768 Announcements on Live Market Tracking →